Chase Richard

Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors

Theresa A. Storm, Patricia A. Lovelace, I. Weissman, 2017, Science Translational Medicine.

Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo

I. Weissman, G. Hutter, R. Majeti, 2016, PloS one.

Neural Placode Tissue Derived From Myelomeningocele Repair Serves as a Viable Source of Oligodendrocyte Progenitor Cells.

I. Weissman, G. Creasey, G. Hutter, 2015, Neurosurgery.

Decoupling of tumor-initiating activity from stable immunophenotype in HoxA9-Meis1-driven AML.

G. Nolan, Angelica Trejo, Kenneth D. Gibbs, 2012, Cell stem cell.

Abstract 5218: Development of Anti-CD47 therapy for pediatric brain tumors.

I. Weissman, Yoon-Jae Cho, A. Achrol, 2013 .

Decoupling of tumor-initiating activity from stable immunophenotype in HoxA9-Meis1-driven AML.

G. Nolan, Angelica Trejo, Kenneth D. Gibbs, 2012, Cell Stem Cell.